Long-term efficacy, safety and tolerability of secukinumab in children and adolescents with severe chronic plaque psoriasis: Two-year results from a Phase III double-blind, randomized controlled trial.

Krasowska, D; Gambichler, T; Cortés, C; Horev, A; Compagno, N; Dahale, S S; Papanastasiou, P; Keefe, D

Krasowska, D; Gambichler, T; Cortés, C; Horev, A; Compagno, N; Dahale, S S; Papanastasiou, P; Keefe, D.

Afiliación

Krasowska D; Department of Dermatology, Venerology and Paediatric Dermatology, Medical University of Lublin, Lublin, Poland.
Gambichler T; Department of Dermatology, Ruhr-University Bochum, Bochum, Germany.
Cortés C; Department of Dermatology, La Samaritana University Hospital, Dermatology Program National University of Colombia, Pontificia Universidad Javeriana and Los Andes University, Bogotá, Colombia.
Horev A; Pediatric Dermatology Service, Soroka University Medical Centre, Beer Sheva, Israel.
Compagno N; Novartis Pharma AG, Basel, Switzerland.
Dahale SS; IQVIA, Mumbai, India.
Papanastasiou P; Novartis Pharma AG, Basel, Switzerland.
Keefe D; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.

J Eur Acad Dermatol Venereol ; 2023 Mar 27.

Article en En | MEDLINE | ID: mdl-36971771

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Tipo de estudio: Clinical_trials Idioma: En Revista: J Eur Acad Dermatol Venereol Asunto de la revista: DERMATOLOGIA / DOENCAS SEXUALMENTE TRANSMISSIVEIS Año: 2023 Tipo del documento: Article País de afiliación: Polonia

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google